RPRX
Royalty Pharma plcMarquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $0.00 | $2.28 | — |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $2.28 | — |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $0.00 | $2.28 | — |
| Point72 Asset Management re-entered | Q4 2024(8Q snapshot) | 6Q | $0.00 | $2.28 | — |
| Citadel Advisors re-entered | Q1 2025(8Q snapshot) | 5Q | $0.00 | $2.28 | — |
| Renaissance Technologies re-entered | Q3 2025(8Q snapshot) | 3Q | $1.56 | $2.28 | +46% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Millennium Management | Q3 2024 | Q2 2026 | — | +0% |
| Viking Global Investors | Q3 2020 | Q4 2025 | — | +0% |
| Bridgewater Associates 4× in & out | Q1 2025 | Q2 2025 | — | +0% |
| Berkshire Hathaway | Q4 2021 | Q3 2022 | — | +0% |
| Maverick Capital | Q2 2021 | Q3 2021 | — | +0% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Royalty Pharma plc. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 8, 2026 — the most recent Form 4 on file — not from today.
- Form 40001188681-26-000003Jun 8, 2026
- Form 40001405104-26-000004Jun 8, 2026
- Form 40001188919-26-000008Jun 8, 2026
- Form 40001193346-26-000004Jun 8, 2026
- Form 40001724605-26-000007Jun 8, 2026
- Form 40001796439-26-000003Jun 8, 2026
- Form 40001704317-26-000006Jun 8, 2026
- Form 40001683607-26-000012Jun 8, 2026
- Form 40001814876-26-000022May 28, 2026
- Form 40001838139-26-000018May 21, 2026
- Form 40001838139-26-000016May 15, 2026
- Form 40001405104-26-000002May 15, 2026
- Form 40001507678-26-000004May 8, 2026
- Form 40001814876-26-000020May 8, 2026
- Form 40001814238-26-000007May 8, 2026
Fundamentals
XBRL · Royalty Pharma plcAnnual figures sourced directly from Royalty Pharma plc's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Royalty Pharma plc — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 4, 2026
- 8-KMaterial eventMay 28, 2026
- 10-QQuarterly reportMay 6, 2026
- 8-KMaterial eventMay 6, 2026
- 8-KMaterial eventApr 13, 2026
- DEF 14AProxy statementApr 10, 2026
- 10-KAnnual reportFeb 11, 2026
- 8-KMaterial eventFeb 11, 2026
- 8-KMaterial eventDec 22, 2025
- 8-KMaterial eventDec 22, 2025
- 10-QQuarterly reportNov 5, 2025
- 8-KMaterial eventNov 5, 2025
- 8-KMaterial eventSep 16, 2025
- 8-KMaterial eventAug 13, 2025
- 10-QQuarterly reportAug 6, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q2 2026 | open | $2.30 | $2.28 | -1% |
| Renaissance Technologies | Q2 2026 | open | $0.00 | — | +0% |
| Point72 Asset Management | Q1 2026 | open | $0.00 | — | +0% |
| Renaissance Technologies | Q3 2025 | Q1 2026 | $1.56 | $3.52 | +125% |
| Citadel Advisors | Q1 2025 | open | $0.00 | — | +0% |
| Bridgewater Associates | Q1 2025 | Q2 2025 | $0.00 | — | +0% |
| Point72 Asset Management | Q4 2024 | Q2 2025 | $0.00 | — | +0% |
| Two Sigma Investments | Q3 2024 | open | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | open | $0.00 | — | +0% |
| D.E. Shaw | Q3 2024 | open | $0.00 | — | +0% |
| AQR Capital Management | Q3 2024 | open | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | Q2 2026 | $0.00 | — | +0% |
| Bridgewater Associates | Q1 2022 | Q4 2024 | $0.00 | — | +0% |
| Berkshire Hathaway | Q4 2021 | Q3 2022 | $0.00 | — | +0% |
| Bridgewater Associates | Q3 2021 | Q4 2021 | $0.00 | — | +0% |
| Maverick Capital | Q2 2021 | Q3 2021 | $0.00 | — | +0% |
| Bridgewater Associates | Q1 2021 | Q2 2021 | $0.00 | — | +0% |
| Viking Global Investors | Q3 2020 | Q4 2025 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.